

DX01170K1 US

**RECEIVED  
CENTRAL FAX CENTER****OCT 29 2007**

**Application 10/749,144  
Draft Claims for Discussion Only  
October 29, 2007**

**33 (New): A method of inhibiting IL-17C activity in a subject with psoriasis, comprising administering to the subject a binding composition, wherein the binding composition comprises an antigen binding site of an antibody that specifically binds to a human IL-17C protein and blocks binding of the IL-17C protein to the extracellular domain of a human IL-17RE protein, wherein the human IL-17C protein comprises the mature sequence in SEQ ID NO:24 and the extracellular domain of the human IL-17RE protein comprises amino acids 1-424 of SEQ ID NO:12.**

**34 (New): The method of Claim 21, wherein the antibody is:**  
**a) a polyclonal antibody;**  
**b) a monoclonal antibody; or**  
**c) a humanized antibody**

**35 (New): The method of Claim 23, wherein the antibody is a humanized antibody.**